vimarsana.com
Home
Live Updates
This Frontline Therapy Is Better in Multiple Myeloma: Study : vimarsana.com
This Frontline Therapy Is Better in Multiple Myeloma: Study
A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.
Related Keywords
United States ,
Florida ,
American ,
Dorisk Hansen ,
,
American Society Of Hematology ,
National Comprehensive Cancer Network ,
Moffitt Cancer Center Research Institute In Tampa ,
Moffitt Cancer Center ,
Research Institute ,
American Society ,
Multiple Myeloma ,
Myeloma ,
Plasma Cell Myeloma ,
Monoclonal Antibody ,
Etuximab ,
Ituximab ,
Transplantation ,
Transplant ,
Biologic Therapy ,
Iologics ,
Proteasome Inhibitor ,
Bortezomib ,
Transplantation Of Stem Cells ,
Ransplantation Of Hematopoietic Stem Cells ,
Hematopoietic Stem Cell Transplant ,
Stem Cell Transplantation ,
Stem Cell Therapy ,
Tem Cell Haematopoietic Stem Transplant ,
vimarsana.com © 2020. All Rights Reserved.